Key result
Continuous intravenous infusion of adriamycin at 3 mg/sq m/day demonstrated clinical activity in various cancers with substantially reduced toxicity compared to standard bolus schedules.
Why the study?
Does a continuous intravenous infusion of adriamycin reduce toxicity while maintaining clinical activity in patients with cancer?
Population
56 patients with various cancers including soft tissue sarcoma, mesothelioma, hepatoma, and breast cancer
Design
Case_series
Follow-up
14-60 days of infusion
Authors
Loading...
Supports evaluation of continuous adriamycin infusion in prospective trials; leaves open confirmation of reduced cardiotoxicity versus bolus.
Does a continuous intravenous infusion of adriamycin reduce toxicity while maintaining clinical activity in patients with cancer?
A 30-day continuous infusion of adriamycin at 3 mg/m2/day reduces toxicity, including potential cardiotoxicity, while maintaining clinical antineoplastic activity.
Lokich et al. (1983) studied Cancer (soft tissue sarcoma, mesothelioma, hepatoma, breast cancer) (n=56). Continuous intravenous infusion of adriamycin was evaluated on Optimal dose, toxicity, and objective response. Continuous intravenous infusion of adriamycin at 3 mg/sq m/day demonstrated clinical activity in various cancers with substantially reduced toxicity compared to standard bolus schedules.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: